Adjuvant therapy in early uterine serous carcinoma
American Journal of Epidemiology · 2026
DOI: 10.1093/aje/kwaf008 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2026. Verfasst von Alison A Garrett und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, UPMC Magee-Womens Hospital, Pittsburgh, PA, United States. Hauptthemen laut MEDLINE: Uterine Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Uterine serous carcinoma (USC) is a rare diagnosis but is associated with high mortality. There are limited data to guide adjuvant treatment decisions in early-stage disease. The purpose of this study is to evaluate the impact of adjuvant therapy on recurrence-free survival (RFS) and overall survival (OS) in early-stage USC. Patients with stage I and II USC treated at a single institution from January 2006 to December 2019 were identified. Demographic, clinicopathologic, treatment, and outcome data were collected. Data were compared using descriptive statistics. Survival analyses were performed using Kaplan-Meier and Cox proportional hazards methods. Ninety-four patients were identified. Median follow-up time was 33.5 months. The median age was 68 years (range, 49-87), the majority of patients were White (n = 78, 83.0%), and the median BMI was 30.7 (range, 14.2-57.3). Minimally invasive surgical staging was performed in 59.6% of cases (n = 56). Most patients had stage IA disease (n = 70, 74.5%). Most patients (n = 79, 84.0%) received adjuvant therapy, and a majority of patients received a combination of systemic chemotherapy and radiation therapy (n = 55, 58.5%), with the most common combination being chemotherapy plus vaginal brachytherapy (n = 42, 44.7%). Most patients (n = 77, 81.9%) remain without evidence of disease, while 17 patients (18.1%) have recurred. Patients receiving 6 cycles of adjuvant chemotherapy experienced improved OS (P = .004) and improved RFS (P = .02) compared to those receiving no adjuvant chemotherapy. Patients with early-stage USC who received 6 cycles of adjuvant chemotherapy had significantly improved OS and RFS when compared to those patients who did not receive adjuvant chemotherapy. This article is part of a Special Collection on Gynecological Cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, UPMC Magee-Womens Hospital, Pittsburgh, PA, United States.
- Division of Gynecologic Oncology, Medical University of South Carolina, Charleston, SC, United States.
- Department of Pathology, UPMC Magee-Womens Hospital, Pittsburgh, PA, United States.
- Division of Gynecologic Oncology, University of Kentucky, Lexington, KY, United States.
- Department of Gynecologic Cancers, Magee-Womens Research Institute, Pittsburgh, PA, United States.
- Department of Radiation Oncology, Allegheny Health Networks, Pittsburgh, PA, United States.
Zitieren
APA
Garrett, A. A., Orellana, T. H., Soong, T. R., Rives, T. A., Taylor, S. E., Coffman, L., Buckanovich, R., Mahdi, H., Beriwal, S., Sukumvanich, P., Bhargava, R., & Olawaiye, A. B. (2026). Adjuvant therapy in early uterine serous carcinoma. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwaf008
Vancouver
Garrett AA, Orellana TH, Soong TR, Rives TA, Taylor SE, Coffman L, et al. Adjuvant therapy in early uterine serous carcinoma. American Journal of Epidemiology. 2026. doi:10.1093/aje/kwaf008
BibTeX
@article{Garrett2026,
author = {Garrett, Alison A and Orellana, Taylor H and Soong, Thing Rinda and Rives, Taylor A and Taylor, Sarah E and Coffman, Lan and Buckanovich, Ronald and Mahdi, Haider and Beriwal, Sushil and Sukumvanich, Paniti and Bhargava, Rohit and Olawaiye, Alexander B},
title = {Adjuvant therapy in early uterine serous carcinoma},
journal = {American Journal of Epidemiology},
year = {2026},
doi = {10.1093/aje/kwaf008}
}
EUVIMED